Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 109.06% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 149.16M.
Fairly Valued
The company’s latest PE is -2.61, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 47.87M shares, decreasing 13.05% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 5.49K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.09.